Pancreatic Cancer Research

ResearcherUniversity of DelawareActive in the last 2 years

Agnieszka Katarzyna Witkiewicz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4538-1145; OpenAlex author ID A5034535391, A5105939568; NIH RePORTER profile ID 9819023. Sources: OpenAlex.

Their work

Papers
35 (first author 2, last author 12)
Trials
0
Grants
2
Labs led
4
Collaborators
89
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: 2 papers · 2014: 3 papers · 2015: 4 papers · 2016: 6 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 1 paper, 1 grant · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers, 1 grant

Papers 35

  1. HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s42003-026-10685-z↗
  2. Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study. Last author DOI 10.1200/po-25-01088↗
  3. Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant. Co-author DOI 10.1007/s10689-025-00475-7↗
  4. Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02408-5↗
  5. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-23-2504↗
  6. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Last author DOI 10.1136/gutjnl-2020-321000↗
  7. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Co-author DOI 10.1038/s41388-019-1102-1↗
  8. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  9. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Co-author DOI 10.1089/pancan.2020.0005↗
  10. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Last author DOI 10.1038/s41388-018-0650-0↗
  11. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  12. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-18-1620↗
  13. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Last author DOI 10.1136/gutjnl-2016-313133↗
  14. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Last author DOI 10.1158/1078-0432.ccr-17-0162↗
  15. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Co-author DOI 10.1016/j.celrep.2015.12.094↗
  16. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.07.023↗
  17. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer ce… Co-author DOI 10.1038/onc.2015.325↗
  18. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Last author DOI 10.1053/j.gastro.2015.08.056↗
  19. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Last author DOI 10.1158/1078-0432.ccr-15-1883↗
  20. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Last author DOI 10.18632/oncotarget.11893↗
  21. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Co-author DOI 10.1038/ncomms7744↗
  22. Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-0744↗
  23. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-14-0199↗
  24. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Co-author DOI 10.18632/oncotarget.3819↗
  25. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Last author DOI 10.1016/j.celrep.2014.11.025↗
  26. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. First author DOI 10.18632/oncotarget.2270↗
  27. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 t… Co-author DOI 10.4161/cbt.28413↗
  28. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-2067↗
  29. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Co-author DOI 10.1158/1541-7786.mcr-12-0699↗
  30. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cncr.26661↗
  31. Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12032-010-9802-y↗
  32. N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer. Co-author DOI 10.1038/onc.2011.574↗
  33. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? Last author DOI 10.1186/1471-2407-12-104↗
  34. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Co-author DOI 10.4161/cbt.20952↗
  35. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. First author DOI 10.1016/j.yasu.2011.04.002↗

Grants 2

  1. Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment R01CA275081↗
  2. Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer R01CA211878↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Erik S. Knudsen · 23 shared papers, 2 shared grants, 2014–2026 · strength 4.57
  2. Vishnu Muthuraj Kumarasamy · 5 shared papers, 2019–2025 · strength 0.79
  3. Ethan V. Abel · 3 shared papers, 2024–2026 · strength 0.72
  4. Kenan Onel · 2 shared papers, 2025–2026 · strength 0.57
  5. Christos K Fountzilas · 2 shared papers, 2025–2026 · strength 0.57
  6. Kennedy S. Humphrey · 2 shared papers, 2025–2026 · strength 0.51
  7. Katherine J. Crawford · 2 shared papers, 2025–2026 · strength 0.51
  8. Jonathan Robert Brody · 11 shared papers, 2011–2016 · strength 0.45
  9. Charles J. Yeo · 11 shared papers, 2011–2016 · strength 0.41
  10. Sejin Chung · 3 shared papers, 2019–2021 · strength 0.34
  11. Leonid Cherkassky · 1 shared paper, 2026 · strength 0.30
  12. Thomas N. O’Connor · 1 shared paper, 2026 · strength 0.30
  13. Riya Jayesh Patel · 1 shared paper, 2025 · strength 0.27
  14. Michael E. Feigin · 1 shared paper, 2025 · strength 0.23
  15. Karen M. Mann · 1 shared paper, 2025 · strength 0.23
  16. Prasenjit Dey · 1 shared paper, 2024 · strength 0.21
  17. Jorge Franco · 3 shared papers, 2014–2016 · strength 0.20
  18. Emanuel F. Petricoin · 3 shared papers, 2016–2020 · strength 0.19
  19. Jordan Michael Winter · 5 shared papers, 2012–2016 · strength 0.18
  20. Cody R. Eslinger · 2 shared papers, 2016–2018 · strength 0.15
  21. Eileen Mary O'Reilly · 2 shared papers, 2016 · strength 0.14
  22. Bjoern Papke · 2 shared papers, 2019–2020 · strength 0.14
  23. Nina V. Chaika · 2 shared papers, 2019–2020 · strength 0.14
  24. Yan Liang · 2 shared papers, 2019–2020 · strength 0.14
  25. J. Nathaniel Diehl · 2 shared papers, 2019–2020 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.